Table 1.

Demographics of respondents

Classification	Question
I. General Matters
(I‐1) Background	(I‐1‐①) Practice years
(I‐2) Changes in attitude	(I‐2‐①) Anti‐VEGF therapy changed your therapeutic strategies for DME treatment?
	(I‐2‐②) Anti‐VEGF is more effective than STTA?
(I‐3) Management before and after Injection	(I‐3‐①) How do you use topical antibiotics?
	(I‐3‐②) When is the initial examination after injection?
II. Treatment Practice Pattern
(II‐1) Initial DME Treatment	(II‐1‐①) What kind of therapy is used as the initial therapy for DME (multiple choice)
(II‐2) Anti‐VEGF Treatment regimen	(II‐2‐①) When did you decide to use anti‐VEGF for DME for the first time?
	(II‐2‐②) What is the most important assessment indicator for initial therapeutic intervention?
	(II‐2‐③) How many anti‐VEGF injections for DME do you perform? (loading phase)
	(II‐2‐④) How do you treat anti‐VEGF injections for DME after an effective loading phase? (maintenance phase)
	(II‐2‐⑤) Maximum number of anti‐VEGF injections you perform before incorporating other therapy
	(II‐2‐⑥) What is an important problem of anti‐VEGF treatment for DME?
III. Alternative Therapy
(III‐1) Combination Therapy	(III‐1‐①) What kind of combination therapy with anti‐VEGF treatment is used for DME? (multiple choice)
	(III‐1‐②) Which systemic disorder you pay attention with anti‐VEGF treatment for DME? (multiple choice)
(III‐2) Alternative use of anti‐VEGF agents	(III‐2‐①) Do you use two approved anti‐VEGF agents (ranibizumab and aflibercept) properly?
	(III‐2‐②) On what basis do you distinguish them?

DME, diabetic macular edema; STTA, sub‐Tenon triamcinolone acetonide injection; VEGF, vascular endothelial growth factor.